Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a position statement of the Acute Leukemia Working Party of the European Society for blood and marrow transplantation

Giebel, Sebastian, Czyz, Anna, Ottmann, Oliver ORCID: https://orcid.org/0000-0001-9559-1330, Baron, Frederic, Brissot, Eolia, Ciceri, Fabio, Cornelissen, Jan J., Esteve, Jordi, Gorin, Norbert-Claude, Savani, Bipin, Schmid, Christoph, Mohty, Mohamad and Nagler, Arnon 2016. Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a position statement of the Acute Leukemia Working Party of the European Society for blood and marrow transplantation. Cancer 122 (19) , pp. 2941-2951. 10.1002/cncr.30130

Preview

PDF - Accepted Post-Print Version Download (224kB) | Preview

Abstract

Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a standard of care for patients with Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia (ALL). The introduction of tyrosine kinase inhibitors (TKIs) to first-line therapy has improved overall outcomes; however, a significant proportion of patients still relapse after alloHSCT. Posttransplant TKI maintenance was demonstrated to reduce the risk of relapse in a large retrospective study and, therefore, should be considered a valuable option. This consensus paper, written on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, presents an overview of clinical studies on the use of TKIs after alloHSCT and proposes practical recommendations regarding the choice of TKI, treatment timing, and dosage. It is hoped that these recommendations will become the state of art in this field and, more importantly, lead to a reduction of Ph-positive ALL relapse after alloHSCT. Cancer 2016;122:2941-2951. © 2016 American Cancer Society.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > R Medicine (General)
Uncontrolled Keywords:	allogeneic hematopoietic stem cell transplantation; dasatinib; imatinib; maintenance therapy; nilotinib; Philadelphia chromosome–positive acute lymphoblastic leukemia; recommendations; tyrosine kinase inhibitors
Publisher:	Wiley
ISSN:	0008-543X
Date of First Compliant Deposit:	9 October 2017
Date of Acceptance:	19 April 2016
Last Modified:	02 Dec 2024 20:30
URI:	https://orca.cardiff.ac.uk/id/eprint/96746

Citation Data

Cited 91 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item